cost of Kadcyla a ground breaking breast cancer drug that the National Health Service or NHS deemed too expensive for routine use. The breast cancer drug has been slated for phase out in 2016 even though it can reportedly “add months of life to women dying of breast cancer.”
The breast cancer drug is praised on several points including how it “attacks cancerous cells from within” thereby avoiding a significant amount of the side effects of chemotherapy is believed to be potentially able to aid “a fifth ofbreast cancer sufferers” according to online sources.
Breast CancerMedication/Image: womens-health-advice
NICE Chief Executive Sir Andrew Dillon asked that the company review its pricing policies. He also stated: “We hope the manufacturer will act in the best interests of patients and use this consultation period to look again at their evidence and consider if there is more they can do (to reduce the price of the treatment).”
Roche’s General Manager, Jayson Dallas, responded to NICE stating that “Roche is extremely disappointed that NICE has failed to safeguard the interests of patients with this advanced stage of aggressive disease.” He stated further that he was hopeful that NICE would “arrive at a sustainable solution that builds upon the success” of the Cancer Drugs Fund, and enables patients to “continue to have rapid access to much needed cancer medicines.” Dallas also argues that the price of the breast cancer drug must take into account expensive “research and development liabilities.”
One breast cancer survivor from Ontario, California brought things closer to home saying: “I was very fortunate to survive this life-threatening disease. I know I was somehow lucky. Still, the whole (treatment) process is trying at times and anything such as this breast cancer drug–which could make life easier–shouldn’t be casually tossed by the wayside because some cannot afford it.”
Source:
0 comments:
Post a Comment